Ultrafine nanoparticles as multimodal contrast agent
US-2015050217-A1 · Feb 19, 2015 · US
US11512003B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11512003-B2 |
| Application number | US-201816620413-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 8, 2018 |
| Priority date | Jun 9, 2017 |
| Publication date | Nov 29, 2022 |
| Grant date | Nov 29, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to a method for synthesizing ultrasmall silica nanoparticles, useful in particular for diagnostics and/or therapy. More specifically, a method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: —the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0≤A≤6, —the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0≤B≤5, —the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0<C≤8. The invention also relates to the obtained ultrasmall silica nanoparticles.
Opening claim text (preview).
The invention claimed is: 1. A method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0≤A≤6; the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0≤B≤5; the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0<C≤8, wherein said nanoparticles, dispersed in water, have a mean hydrodynamic diameter between 0.5 and 15 nm, and wherein all the silanes represent at least 80% by weight of the total weight of the reagents. 2. The method according to claim 1 , wherein all the silanes are chosen among alkoxysilanes, hydroxysilanes, and mixture thereof. 3. The method according to claim 1 , wherein the mixing step is performed in a protic solvent. 4. The method according to claim 1 , wherein said method is a one-pot synthesis without any isolation or purification step of the intermediate product(s). 5. The method according to claim 1 , wherein the silica nanoparticles do not comprise a crystalline core. 6. The method according to claim 1 , wherein said negatively charged silane(s) includes silane(s) comprising at least one, two, or more negatively charged carboxylic acid functions. 7. The method according to claim 1 , wherein said negatively charged silane(s) includes silane(s) comprising at least one chelating agent. 8. The method according to claim 7 , wherein said chelating agent is chosen from polyamino polycarboxylic acids including without limitation: DOTA (1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid), DOTAGA (2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid), DO3A-pyridine of formula (III) below: DTPA (diethylenetriaminepentaacetic acid), CHX-DTPA (trans-cyclohexyl-diethylenetriaminepentaacetic acid), oxo-Do3A (1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid), SCN-Bz-DTPA (p-isothiocyanatobenzyl-DTPA), 1 B3M (1-(p-isothiocyanatobenzyl)-3-methyl-DTPA), MX-DTPA (1-(2)-methyl-4-isocyanatobenzyl-DTPA); EDTA (2,2′,2″,2′″-(ethane-1,2-diyldinitrilo)tetraacetic acid); EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid), BAPTA (1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid); NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid); PCTA (3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid); TMPAC of formula (N) below: and mixtures thereof. 9. The method according to claim 7 , wherein said chelating agent(s) is(are) free of metallic ions. 10. The method according to claim 7 , wherein said chelating agent(s) is(are) chelating a metallic ion including alkali metal ions and their radioactive isotopes, transition metal ions and their radioactive isotopes, post-transition metal ions and their radioactive isotopes, rare earth metal ions and their radioactive isotopes, and mixtures thereof. 11. The method according to claim 1 , wherein said positively charged silane(s) includes at least a silane with one positively charged amino function. 12. The method according to claim 1 , wherein the mixing step further includes at least one silane comprising at least one fluorophore, the molar ratio D of silane(s) comprising a fluorophore to neutral silane(s) being defined as follows: 0.001≤D≤0.2. 13. The method according to claim 1 , wherein the mixing step further includes at least one silane comprising at least one drug moiety, the molar ratio E of silane(s) comprising a drug to neutral silane(s) is defined as follows: 0.1≤E≤5. 14. Method according to claim 13 , wherein the nanoparticles comprise between 0.5 and 50% by weight of drug moiety as compared to the total weight of the nanoparticle. 15. The method of claim 1 , wherein the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0.5≤A≤2. 16. The method of claim 1 , wherein the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0.25≤B≤3. 17. The method of claim 1 , wherein the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 1<C≤4. 18. The method of claim 1 , wherein said nanoparticles, dispersed in water, have a mean hydrodynamic diameter between 0.5 and 10 nm. 19. The method of claim 13 , wherein the nanoparticles comprise between 2 and 10% by weight of drug moiety as compared to the total weight of the nanoparticle.
having a (super)(para)magnetic core coated or functionalised with a small organic molecule (oligomeric, polymeric, dendrimeric A61K49/1851) · CPC title
Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title
characterised by the carrier · CPC title
using functional images, e.g. PET or MRI · CPC title
Nanometer sized, i.e. from 1-100 nanometer · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.